TickerFiles

Amphastar Pharmaceuticals, Inc. 10-Q filing

Filed 2025-08-07 · Report date 2025-06-30 · 2025

View Original SEC Filing

Filing metadata

Accession number
0001297184-25-000050
Form type
10-Q
CIK
0001297184
Primary document
https://www.sec.gov/Archives/edgar/data/1297184/000129718425000050/amph-20250630x10q.htm

Extracted primary information

This filing includes deterministic financial metrics extracted from public filing data for Amphastar Pharmaceuticals, Inc..

Reported financial metrics

MetricCurrentPriorChange
Revenue$344.9M--
Cost Of Revenue$173.2M--
Gross Profit$171.7M--
Operating Income$79.5M--
Net Income$56.3M--
Eps Basic1.19--
Eps Diluted1.15--
Cash And Equivalents$187.7M--
Total Assets$1.6B--
Total Liabilities$857.9M--
Operating Cash Flow$70.7M--
Capital Expenditures$21.3M--